PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients.xlsx

PD-L1 is a tumor marker that co-stimulates the receptor PD-1 to suppress T-cell-mediated antitumor immunity. Seventy-six biopsy sample were taken from patients diagnosed with penile squamous cell carcinoma who have already undergone penile biopsy. PD-LI expression was assessed on cytoplasm and/or tumor cell membranes and TILs. PD-LI staining was performed on 500 tumor cells and 100 TILs. Semi-quantitative assessment refers to research by Chovanec <em>et al.</em> who used histoscore (H-score). The percentage of stained cells was assessed on a scale of 0-100%. Intensity measurement then given a score of 0-3 (0= none; 1= weak; 2= moderate; and 3= strong).<br> <br>

程序性死亡配体1（PD-L1）是一种可共刺激程序性死亡受体1（PD-1）并抑制T细胞介导的抗肿瘤免疫的肿瘤标志物。本数据集纳入76份活检样本，均取自已接受阴茎活检的阴茎鳞状细胞癌患者。研究针对细胞质和/或肿瘤细胞膜以及肿瘤浸润淋巴细胞（Tumor Infiltrating Lymphocytes, TILs）的PD-L1表达水平进行评估。研究人员对500个肿瘤细胞与100个肿瘤浸润淋巴细胞实施了PD-L1染色。

半定量评估参照Chovanec等学者的研究方法，采用组织学评分（histoscore, H-score）。其中，染色细胞的占比以0~100%的区间进行评分，染色强度则被赋值为0至3分：0代表无染色，1代表弱染色，2代表中等强度染色，3代表强染色。